Brain White Matter Diseases, Diffusion Magnetic Resonance Imaging
Conditions
Brief summary
To assess the sensitivity and accuracy of diffusion magnetic resonance imaging (MRI), including diffusion-weighted imaging (DWI) metrics, in identifying early-stage changes in brain white matter related to various white matter diseases.
Detailed description
Brain white matter diseases (WMDs) are a group of neurological conditions that involve changes to the brain's white matter, often leading to cognitive, motor, and sensory impairments. Diffusion Magnetic Resonance Imaging (dMRI), has emerged as a powerful non-invasive imaging tool for evaluating microstructural changes in brain white matter. This protocol aims to investigate the role of dMRI in the early identification and characterization of brain white matter diseases, focusing on its potential for detecting abnormalities before the onset of overt clinical symptoms. Diffusion-weighted imaging (DWI), one of the first advanced magnetic resonance imaging (MRI) techniques, has rapidly ascended on the basis of its applicability in strokes and some infectious diseases. Restricted diffusion is significant information in the context of vascular ischemia, helping to delimit the brain-damaged area
Interventions
OTHERMagnetic Resonance Imaging (MRI)
Magnetic Resonance Imaging (MRI) Scanner: All imaging will be performed using a 1.5 tesla MRI scanner to ensure high resolution and signal-to-noise ratio.
Sponsors
The General Authority for Teaching Hospitals and Institutes
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Adults aged 18-80 years. * Clinical suspicion of early-stage white matter disease. * No prior diagnosis of significant neurological disorders (e.g., stroke, brain tumors). * Ability to provide informed consent.
Exclusion criteria
* Pregnancy or breastfeeding. * Contraindications for magnetic resonance imaging (MRI) (e.g., metal implants, pacemakers). * Severe psychiatric or cognitive impairment that prevents participation. * Control Group: Healthy individuals without any clinical history of neurological diseases, matched by age and sex to the patient cohort.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity of diffusion magnetic resonance imaging | Immediately after diffusion magnetic resonance imaging (Up to 1 hour) | Sensitivity of diffusion magnetic resonance imaging to predict the early evaluation of brain white matter diseases |
Countries
Egypt
Contacts
Primary ContactHekmat S Baumey, MD
Outcome results
None listed